Lupin out-licenses novel blood cancer drug to AbbVie deal

Lupin out-licenses novel blood cancer drug to AbbVie deal

Lupin, India’s third largest drug maker, on December 24 said it has licensed out its first-in-class blood cancer drug candidate to US-based biopharmaceutical company AbbVie.

Lupin out-licenses novel blood cancer drug to AbbVie deal

Through this deal, AbbVie gains exclusive global rights to develop and commercialize Lupin’s MALTl inhibitors.

MALTl is an immuno-oncology drug that activates T-cell and B-cell lymphocytes to target and kill cancer cells. Drugs that stimulate body’s own immune system to fight cancer, have been sought-out after, as they are more specific at targeting cancer cells with least side-effects.

AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options.

Under the terms of the agreement, AbbVie will pay Lupin an upfront payment of $30 million for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to $947 million.

Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.

The deal licensing deal with AbbVie marks a major breakthrough for Lupin’s drug discovery efforts, which started way back in 2010 with a focus to address unmet medical needs in the therapeutic areas of Oncology, Immunology and Metabolic disorders.

“Delivering on new drugs was a key element of Dr. Deshbandhu Gupta’s vision. We are extremely proud of being able to realize his vision to bring new treatments to patients in need,” said Nilesh Gupta, Managing Director of Lupin.

“This is a first-in-class drug discovery program delivered exclusively by Lupin right from concept generation through the various stages of drug discovery and development,” said Raj Kamboj, President of Lupin’s Novel Drug Discovery and Development (NDDD).

“Lupin’s MALTl program is exploring a new and innovative approach in difficult-to-treat cancers. AbbVie is committed to pursuing advanced treatment options for patients and we look forward to partnering our expertise in hematological oncology with Lupin’s discovery program to offer new hope to patients, ” Tom Hudson, Vice President, of Discovery at AbbVie said.

source: moneycontrol